目的 比較托莫西汀和阿立哌唑治療兒童注意缺陷多動(dòng)障礙的臨床療效。方法 收集2015年1月-2016年1月在大連市第七人民醫(yī)院診治的88例注意缺陷多動(dòng)障礙患者，根據(jù)用藥方案的不同分為對(duì)照組和治療組，每組各44例。對(duì)照組患兒口服阿立哌唑片，1片/次，每晚1次。治療組患兒口服鹽酸托莫西汀膠囊，初始劑量為每天0.5 mg/kg，治療過(guò)程中根據(jù)臨床反應(yīng)及耐藥性進(jìn)行劑量調(diào)整，每天最大劑量為1.4 mg/kg。兩組患兒均連續(xù)治療6周。比較兩組患兒臨床效果、SNAP-IV量表評(píng)分、數(shù)字劃消失誤率和Conners父母量表測(cè)驗(yàn)結(jié)果。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.82%、97.73%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患兒SNAP-IV量表評(píng)分、數(shù)字劃消失誤率和Conners父母量表測(cè)驗(yàn)結(jié)果均顯著改善，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組患兒上述觀察指標(biāo)比對(duì)照組的改善更明顯，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 托莫西汀治療注意缺陷多動(dòng)障礙臨床效果顯著，有利于患者認(rèn)知功能的改善，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To compare the clinical efficacy of aripiprazole and atomoxetine in treatment of children with attention deficit hyperactivity disorder. Methods Children (88 cases) with attention deficit hyperactivity disorder in Dalian Seventh People's Hospital from January 2015 to January 2016 were divided into control and treatment groups based on different treatments, and each group had 44 cases. Children in the control group were po administered with Aripiprazole Tablets, 1 tablet/time, once per night. Children in the treatment group were po administered with Atomoxetine Hydrochloride Capsules., The initial dosage was 0.5 mg/kg daily, and which was adjusted according to clinical response and drug resistance, and the maximum dosage was 1.4 mg/kg daily. Children in two groups were treated for 6 weeks. After treatment, the clinical efficacy, SNAP-IV scores, digital cancellation error rate, and Conners parents scale Results in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P<0.05). After treatment, SNAP-IV scores, digital cancellation error rate, and Conners parents scale Results in two groups were significantly improved, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Atomoxetine has a significant clinical effect in treatment of children with attention deficit hyperactivity disorder, which is conducive to improve the cognitive function, and has a certain clinical application value.